Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gallbladder neoplasia is associated with a higher incidence of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Canadian liver journal·2026
Same author

Betaine in the treatment of steatotic liver disease-Historical fad or a timeless treasure worth reviving?

Hepatology (Baltimore, Md.)·2025
Same author

Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis.

Gastro hep advances·2024
Same author

Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.

JHEP reports : innovation in hepatology·2023
Same author

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.

Liver international : official journal of the International Association for the Study of the Liver·2023
Same author

Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.

Hepatology (Baltimore, Md.)·2023
Same journal

Immediate prediction of post-ERCP pancreatitis: a novel approach using serum trypsin.

Journal of gastroenterology·2026
Same journal

Enhanced COMP expression induced by Helicobacter pylori drives gastric cancer progression by NOTCH2/SMAD3 pathway.

Journal of gastroenterology·2026
Same journal

Comment on "Dependence-related screening positivity among regular stimulant-laxative users with chronic constipation: a multicenter prospective observational study".

Journal of gastroenterology·2026
Same journal

Comment on "Dependence-related screening positivity among regular stimulant-laxative users with chronic constipation: a multicenter prospective observational study".

Journal of gastroenterology·2026
Same journal

METTL3/FTO drives ferroptosis in colorectal cancer by targeting m<sup>6</sup>A modification of MUC1 mRNA and YTHDF2-dependent SLC7A11/GSH pathway.

Journal of gastroenterology·2026
Same journal

Risk of lymph-node metastasis in early onset T1 colorectal cancer: a systematic review and meta-analysis.

Journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Autoimmune hepatitis: a review.

Andrea A Gossard1, Keith D Lindor

  • 1Mayo Clinic, Rochester, MN 55901, USA. Gossard.andrea@mayo.edu

Journal of Gastroenterology
|April 25, 2012
PubMed
Summary
This summary is machine-generated.

Autoimmune hepatitis (AIH) is a severe liver inflammation primarily affecting females. Prompt immunosuppressive treatment can induce remission, allowing for a normal life expectancy, though some may progress to cirrhosis or require transplantation.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Related Experiment Videos

Last Updated: May 22, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Area of Science:

  • Hepatology
  • Immunology
  • Internal Medicine

Background:

  • Autoimmune hepatitis (AIH) is an inflammatory liver condition.
  • It predominantly affects females and can impact both children and adults.
  • AIH is characterized by interface hepatitis, elevated liver enzymes, autoantibodies, and high immunoglobulin G levels.

Purpose of the Study:

  • To provide an overview of autoimmune hepatitis.
  • To discuss the clinical presentation, diagnosis, and management of AIH.
  • To highlight the importance of prompt treatment and potential long-term outcomes.

Main Methods:

  • This abstract summarizes key aspects of AIH based on established medical knowledge.
  • Information presented includes histological, biochemical, and serological diagnostic criteria.
  • Treatment strategies and prognostic factors are discussed.

Main Results:

  • AIH is a rare but serious disease requiring timely immunosuppressive therapy.
  • Treatment can effectively induce remission, potentially leading to normal life expectancy.
  • Disease progression to cirrhosis and complications necessitating liver transplantation can occur.

Conclusions:

  • Early diagnosis and prompt immunosuppressive treatment are crucial for managing autoimmune hepatitis.
  • While remission is achievable, long-term monitoring is necessary due to the risk of cirrhosis.
  • Liver transplantation remains an option for advanced cases.